fbpx

YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Indonesia Aims To Combat Growing Cervical Cancer Issues With Merck’s HPV Vaccines – $MRK $DIA $IBB $ATOS

By John F. Heerdink, Jr.
According to the World Health Organization, cervical cancer is the fourth most common cancer among women globally, with an estimated 604,000 new cases and 342,000 deaths in 2020. In Indonesia, the disease took the lives of more than 36,000 people in 2021.


Reportedly, Indonesia will produce drugmaker Merck’s (MRK) vaccines for human papillomavirus (HPV), informed the chief of its state-owned pharmaceutical company Bio Farma in a bid to combat HPV-linked cervical cancer in the country.

Honesti Basyir, chief of Bio Farma, signed a technology transfer deal with Merck & Co, one of the world’s main makers of HPV vaccines, to help produce the Merck shots in the country. The country authorities aim to give the shots to 1.4 million girls next year, adding it aims to produce 2.8 million doses given the two-shot regime recommended to inoculate against HPV-linked cervical cancer. 


Merck & Co., Inc. (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some of the world’s most challenging diseases for more than a century. They are committed to increasing healthcare access and continue to be at the leading edge of research. Merck has the industry’s largest immuno-oncology clinical research program. To learn more about Merck (MRK) and to track its ongoing progress please visit the Vista Partners Merck Coverage Page.

If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a current focus on breast cancer and lung injury caused by cancer treatments.

 
 
 
Stay Informed! Stay Competitive! Please join us at Vista Partners to receive our FREE email updates throughout the week and view our exclusive content and research. Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
 
 
(Read Original Story: Indonesia to produce Merck's HPV vaccines to combat cervical cancer in Reuters)


YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us